0001179110-18-004702.txt : 20180320 0001179110-18-004702.hdr.sgml : 20180320 20180320173633 ACCESSION NUMBER: 0001179110-18-004702 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180316 FILED AS OF DATE: 20180320 DATE AS OF CHANGE: 20180320 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hack Andrew A. F. CENTRAL INDEX KEY: 0001657434 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37687 FILM NUMBER: 18702753 MAIL ADDRESS: STREET 1: 300 THIRD STREET, FIRST FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Editas Medicine, Inc. CENTRAL INDEX KEY: 0001650664 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464097528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11 HURLEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-401-9000 MAIL ADDRESS: STREET 1: 11 HURLEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 edgar.xml FORM 4 - X0306 4 2018-03-16 0 0001650664 Editas Medicine, Inc. EDIT 0001657434 Hack Andrew A. F. C/O EDITAS MEDICINE, INC. 11 HURLEY ST. CAMBRIDGE MA 02141 0 1 0 0 Chief Financial Officer Common Stock 2018-03-16 4 M 0 6000 6.48 A 6000 D Common Stock 2018-03-16 4 S 0 6000 39.43 D 0 D Common Stock 2018-03-19 4 M 0 6000 6.48 A 6000 D Common Stock 2018-03-19 4 S 0 6000 37.65 D 0 D Common Stock 2018-03-20 4 M 0 5000 6.48 A 5000 D Common Stock 2018-03-20 4 S 0 5000 37.51 D 0 D Common Stock 2018-03-20 4 M 0 1000 6.48 A 1000 D Common Stock 2018-03-20 4 S 0 1000 38.39 D 0 D Common Stock 2018-03-20 4 M 0 22000 24.6 A 22000 D Common Stock 2018-03-20 4 S 0 22000 37.91 D 0 D Stock Option (right to buy) 6.48 2018-03-16 4 M 0 6000 0 D 2025-09-13 Common Stock 6000 60513 D Stock Option (right to buy) 6.48 2018-03-19 4 M 0 6000 0 D 2025-09-13 Common Stock 6000 54513 D Stock Option (right to buy) 6.48 2018-03-20 4 M 0 6000 0 D 2025-09-13 Common Stock 6000 48513 D Stock Option (right to buy) 24.60 2018-03-20 4 M 0 22000 0 D 2027-02-28 Common Stock 22000 70500 D The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017. This transaction was executed in multiple trades at prices ranging from $39.02 to $40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $37.29 to $38.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $37.13 to $38.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $38.23 to $38.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $37.86 to $38.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019. This amount includes an additional 2,851 option shares relating to the portion of this award constituting an Incentive Stock Option that the Reporting Person inadvertently omitted in that Form 4 filed by the Reporting Person with the SEC on February 16, 2018. This option was granted on March 1, 2017 and is scheduled to vest over four years in equal monthly installments beginning on March 1, 2017 through March 1, 2021. /s/ Andrew Hack 2018-03-20